{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-071769","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.145353+00:00","generated_at":"2026-05-17T23:29:16.521744+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded","bullets":["Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.","Court previously granted CG Oncology's partial summary judgment on Brulotte defense, finding royalty provision unenforceable.","ANI intends to challenge the verdict through post-trial motions and/or an appeal.","Case stems from a 2010 Agreement for a 5% royalty on worldwide net sales of cretostimogene."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-071769","json":"https://secwatch.observer/filing/0001104659-25-071769.json","markdown":"https://secwatch.observer/filing/0001104659-25-071769.md","text":"https://secwatch.observer/filing/0001104659-25-071769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/0001104659-25-071769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/tm2522000d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:29:16.521744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}